K-J Winzer1, C Gruber, H Badakhshi, M Hinkelbein, C Denkert. 1. Brustzentrum, Klinik für Gynäkologie, Charité am Campus Benjamin Franklin und am Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Deutschland. klaus-juergen.winzer@charite.de
Abstract
BACKGROUND AND PURPOSE: In this study, we investigated how often guidelines for radiation therapy in patients with breast cancer are not complied with, which patient group is mostly affected, and how this influences local recurrence. PATIENTS AND METHODS: All patients (n = 1,903) diagnosed between November 2003 and December 2008 with primary invasive or intraductal breast cancer in the interdisciplinary breast center of the Charité Hospital Berlin were included and followed for a median 2.18 years. RESULTS: Patients who, in contrast to the recommendation of the interdisciplinary tumor board, did not undergo postoperative radiation experienced a fivefold higher local recurrence rate (p < 0.0005), corresponding to a 5-year locoregional recurrence-free survival of 74.5% in this group. The 5-year locoregional recurrence-free survival of patients following the recommendations was 93.3%. Guideline compliance was dependent on age of patients, acceptance of adjuvant hormonal treatment or chemotherapy, and increased diameter of the primary tumor. Multiple logistic regression analysis showed an association between compliance and age or hormonal therapy. CONCLUSION: In order to avoid local recurrence patients should be motivated to comply with guideline driven therapy. Since a higher number of local recurrences is observed in health services research compared to clinical research, studies on the value of adjuvant treatment following local recurrence should be performed.
BACKGROUND AND PURPOSE: In this study, we investigated how often guidelines for radiation therapy in patients with breast cancer are not complied with, which patient group is mostly affected, and how this influences local recurrence. PATIENTS AND METHODS: All patients (n = 1,903) diagnosed between November 2003 and December 2008 with primary invasive or intraductal breast cancer in the interdisciplinary breast center of the Charité Hospital Berlin were included and followed for a median 2.18 years. RESULTS:Patients who, in contrast to the recommendation of the interdisciplinary tumor board, did not undergo postoperative radiation experienced a fivefold higher local recurrence rate (p < 0.0005), corresponding to a 5-year locoregional recurrence-free survival of 74.5% in this group. The 5-year locoregional recurrence-free survival of patients following the recommendations was 93.3%. Guideline compliance was dependent on age of patients, acceptance of adjuvant hormonal treatment or chemotherapy, and increased diameter of the primary tumor. Multiple logistic regression analysis showed an association between compliance and age or hormonal therapy. CONCLUSION: In order to avoid local recurrence patients should be motivated to comply with guideline driven therapy. Since a higher number of local recurrences is observed in health services research compared to clinical research, studies on the value of adjuvant treatment following local recurrence should be performed.
Authors: Matthias W Beckmann; Cosima Brucker; Volker Hanf; Claudia Rauh; Mayada R Bani; Stefanie Knob; Sabrina Petsch; Stefan Schick; Peter A Fasching; Arndt Hartmann; Michael P Lux; Lothar Häberle Journal: Onkologie Date: 2011-06-15
Authors: Juliann Saquib; Lisa Madlensky; Sheila Kealey; Nazmus Saquib; Loki Natarajan; Vicky A Newman; Ruth E Patterson; John P Pierce Journal: Integr Cancer Ther Date: 2011-03-07 Impact factor: 3.279
Authors: Tomasz P Srokowski; Shenying Fang; Zhigang Duan; Thomas A Buchholz; Gabriel N Hortobagyi; James S Goodwin; Sharon H Giordano Journal: Cancer Date: 2008-07-01 Impact factor: 6.860
Authors: K Hancke; M D Denkinger; J König; C Kurzeder; A Wöckel; D Herr; M Blettner; R Kreienberg Journal: Ann Oncol Date: 2009-10-13 Impact factor: 32.976
Authors: S Darby; P McGale; C Correa; C Taylor; R Arriagada; M Clarke; D Cutter; C Davies; M Ewertz; J Godwin; R Gray; L Pierce; T Whelan; Y Wang; R Peto Journal: Lancet Date: 2011-10-19 Impact factor: 79.321
Authors: S Corradini; O M Niemoeller; M Niyazi; F Manapov; M Haerting; N Harbeck; C Belka; S Kahlert Journal: Strahlenther Onkol Date: 2014-02-07 Impact factor: 3.621
Authors: M L Sautter-Bihl; F Sedlmayer; W Budach; J Dunst; P Feyer; R Fietkau; W Haase; W Harms; C Rödel; R Souchon; F Wenz; R Sauer Journal: Strahlenther Onkol Date: 2012-10-28 Impact factor: 3.621